Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Joan T. Garrett, Anindita Chakrabarty, Carlos L. Arteaga

Research output: Contribution to journalComment/debate

Abstract

This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

Original languageEnglish (US)
Pages (from-to)32400
Number of pages1
JournalOncotarget
Volume9
Issue number64
DOIs
StatePublished - Aug 17 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409'. Together they form a unique fingerprint.

  • Cite this